Table 2 Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents before and after availability of generic alternatives
Medication | Monthly cost in gap | Monthly cost in catastrophic | |||||||
|---|---|---|---|---|---|---|---|---|---|
Median of state mean costs | Median of state mean costs | Median of state mean costs | |||||||
$, (Range of mean costs) | $, (Range of mean costs) | $, (Range of mean costs) | |||||||
2007 | 2011 a | Change (%) | 2007 | 2011 a | Change (%) | 2007 | 2011 a | Change (%) | |
Arimidex/Anastrozole | 39.64 (38.37-48.19) | 9.57 (8.00-11.95) | −76 | 258.64 (247.44-263.47) | 38.94 (31.80-78.46) | −85 | 13.18 (12.68-13.32) | 3.72 (3.39-6.19) | −72 |
Aromasin/Exemestane | 42.57 (40.72-50.94) | 49.50 (42.34-118.68) | +16 | 267.56 (255.21-273.62) | 244.51 (228.61-270.95) | −9 | 13.66 (13.07-13.79) | 14.41 (13.51-71.41) | +6 |
Femara/Letrozole | 41.92 (39.38-51.11) | 69.31 (59.69-85.17) | +65 | 277.65 (249.14-282.54) | 225.13 (209.10-252.23) | −19 | 14.16 (12.96-14.34) | 38.53 (33.70-57.15) | +172 |
Tamoxifen | 6.19 (5.95-9.22) | 5.54 (5.12-6.89) | −11 | 21.32 (20.36-25.42) | 13.17 (12.44-21.11) | −38 | 2.26 (2.20-2.70) | 2.73 (2.50-3.47) | +21 |